HBW Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Estee Lauder Skin Care Sales Up 17%, Double-Digit Growth Forecast For 2000

This article was originally published in The Rose Sheet

Executive Summary

Estee Lauder skin care sales increased 17% to $353.4 mil., for the fiscal first quarter (ended Sept. 30), representing the company's fastest growing product category, President and Chief Operating Officer Fred Langhammer told securities analysts during a conference call Oct. 26.

You may also be interested in...



Jo Malone To Remain In Niche Arena Initially Following Lauder Buy, Exec Says

Estee Lauder plans to keep Jo Malone, the newest addition to its beauty care empire, firmly entrenched in the niche arena before expanding the London-based fragrance and skin care company into mainstream department stores.

Origins Expands Top-Selling Salt Rub With Three New Body Products

Origins is extending its Salt Rub Smoothing body scrub with three new bath and body offerings two years after the successful launch of the original product. The new additions will be available in department stores in October.

Estee Lauder To Add 75 To 80 Free-Standing Retail Doors In FY 2000

Estee Lauder will more than double its existing free-standing doors with 75 to 80 new outlets in FY 2000, President and Chief Operating Officer Fred Langhammer told securities analysts during an Aug. 18 conference call. The company, which currently operates approximately 110 stand-alone boutiques, plans to have a total of 400 to 500 doors over the next several years.

Latest Headlines
See All
UsernamePublicRestriction

Register

RS007319

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel